05:05 PM EDT, 10/15/2024 (MT Newswires) -- NovoCure ( NVCR ) said late Tuesday the US Food and Drug Administration has approved its Optune Lua device to treat adults with metastatic non-small cell lung cancer.

The approval is for the simultaneous use of Optune Lua with PD-1/PD-L1 inhibitors or docetaxel in lung cancer patients who have progressed on or after platinum-based chemotherapy, the company said.

Optune Lua is a device that creates alternating electric fields known as tumor treating fields, which are delivered via wearable arrays to kill cancer cells, NovoCure ( NVCR ) said.

NovoCure ( NVCR ) shares jumped nearly 24% in recent after-hours activity.

Price: 22.01, Change: +4.23, Percent Change: +23.79